Mediar Therapeutics Completes Enrollment for Phase 2 IPF Trial

The global study, spanning more than 70 sites in North America, South America, Europe, and Australia, tests the safety and efficacy of intravenous MTX-463 infusions administered every four weeks. Researchers are primarily measuring changes in forced vital capacity over a 24-week period to assess lung function. Jeff Bornstein, Chief Medical Officer at Mediar, noted that the rapid enrollment pace reflects the urgent demand for new therapies in a field where current treatment options remain limited. The trial follows successful Phase 1 testing in healthy volunteers, which confirmed the drug was well tolerated and capable of engaging its intended biological target.

This trial operates under a licensing agreement with Eli Lilly and Company, which retains the rights to lead subsequent development and commercialization once the Phase 2 data is finalized. Beyond the WISPer study, Mediar continues to develop a broader pipeline of therapies targeting other drivers of fibrotic diseases, including EphrinB2 and SMOC2 proteins. The company maintains a specialized focus on neutralizing myofibroblasts, the cells primarily responsible for the organ scarring that characterizes chronic fibrotic conditions.